GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
SYDNEY, Australia, July 16, 2017 -- Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”) today announced it will receive a second undisclosed significant clinical milestone payment from Novartis, based on the collaboration and licensing agreement between the companies, relating to Prima’s IMP701 LAG-3 antibody (also referred to as LAG525).
The LAG525 antibody is currently being evaluated in clinical trials together with Novartis’ PD1 inhibitor PDR001 for the treatment of cancer. Novartis has full responsibility for the continued development of the antibody program and Prima is eligible to receive further potential development-based milestone payments and royalties on sales following commercialisation of the products.
Mr. Marc Voigt, CEO of Prima, commented, "We are very pleased by the progression of the LAG525 program. It is wonderful to see our commercial partners continuing to progress the development of LAG-3 products. This announcement, together with the other clinical and non-clinical data published regarding other LAG-3 directed drug development programs over the past twelve months is very encouraging."
About IMP701
IMP701 is a therapeutic antibody originally developed by Immutep S.A.S to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevent T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway and don’t address the Treg pathway.
IMP701 was licensed to CoStim Pharmaceuticals in 2012 which was subsequently acquired by Novartis in 2014.
About Prima BioMed
Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please contact: Australian Investors/Media: Mr Matthew Gregorowski, Citadel-MAGNUS +61 2 8234 0105; [email protected] U.S. Investors: Matthew Beck, The Trout Group LLC +1 (646) 378-2933; [email protected]
